---
title: EUS Guided Celiac Neurolysis
nct_id: NCT01615653
overall_status: COMPLETED
phase: NA
sponsor: Mayo Clinic
study_type: INTERVENTIONAL
primary_condition: Pancreatic Cancer Pain
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01615653.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01615653"
ct_last_update_post_date: 2017-07-25
last_seen_at: "2026-05-12T07:12:03.913Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# EUS Guided Celiac Neurolysis

**Official Title:** Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain

**NCT ID:** [NCT01615653](https://clinicaltrials.gov/study/NCT01615653)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 110
- **Lead Sponsor:** Mayo Clinic
- **Collaborators:** American College of Gastroenterology
- **Conditions:** Pancreatic Cancer Pain
- **Start Date:** 2009-09
- **Completion Date:** 2015-06
- **CT.gov Last Update:** 2017-07-25

## Brief Summary

* Hypothesis:

  \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma.
* Rationale:

  * Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 1\. Unresectable pancreatic carcinoma (T4 or M1) or advanced T3 disease
* 2\. Cytologic or histologic confirmation of pancreatic carcinoma
* 3\. Abdominal pain (≥ 3 on NRS scale), ≥ 2 days/week, lasting ≥ 1 hour/ day, stable intensity for ≥ 7 days
* 4\. EUS clinically indicated (for non-study purposes)

Exclusion Criteria:

* 1\. Uncorrectable coagulopathy: (INR) \> 1.5 and/or platelets \< 50,000
* 2\. Abdominal surgery within 1 month
* 3\. Prior celiac plexus or ganglia neurolysis.
* 4\. Initiation or modification in chemotherapy or radiotherapy within prior 7 days.
* 5\. Direct tumor infiltration of the celiac trunk and/or celiac ganglia.
```

## Arms

- **EUS 1** (ACTIVE_COMPARATOR)
- **EUS 2** (ACTIVE_COMPARATOR)

## Interventions

- **EUS** (PROCEDURE) — EUS Guided Therapy

## Primary Outcomes

- **Pain assessed using a numerical rating scale (NRS) from 0 to 10.** _(time frame: Baseline to 6 months)_ — pain response will be measured

## Locations (1)

- Mayo Clinic, Rochester, Minnesota, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mayo clinic|rochester|minnesota|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01615653.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01615653*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*